Background-Dual antiplatelet therapy in older versus younger patients with acute coronary syndromes is understudied.
O
ptimizing care for elderly patients with cardiovascular disease constitutes both a central priority and a formidable challenge in contemporary medicine. Given the rapid growth of an aging population worldwide, an increasing proportion of morbidity and mortality related to cardiovascular disease is likely to occur in elderly patients. Hence, whereas persons ≥75 years of age constitute <10% of the US population, they account for 35% of patients with non-ST-segmentelevation acute coronary syndromes (ACS). 1 Despite these demographic realities, elderly patients remain underrepresented in randomized trials for cardiovascular disease, and current ACS treatment guidelines are based primarily on studies comprising largely younger patients. [2] [3] [4] [5] [6] [7] Finally, although age may alter the balance of risk and benefit of therapeutic strategies, trial data on older patients with ACS have usually been limited to subgroup analyses rather than derived from dedicated age-specific studies. [8] [9] [10] [11] [12] [13] [14] [15] Clinical Perspective on p 833
Prasugrel, a thienopyridine P2Y 12 inhibitor, has been shown to reduce the risk of ischemic events compared with clopidogrel in ACS patients undergoing percutaneous coronary intervention with a 60-mg loading dose followed by a 10-mg/d maintenance dose. 16 However, no net clinical benefit was observed with this prasugrel dose in elderly patients (≥75 years of age) owing to an increased hazard of intracranial and fatal bleeding; in addition, higher bleeding rates were demonstrated in patients <75 years of age who were <60 kg in weight. 16 These results led to warnings concerning use of the 10-mg prasugrel dose for elderly and younger, low-bodyweight patients in labeled indications developed by the US Food and Drug Administration and the European Medicines Agency. 17, 18 However, recommendations for a reduced 5-mg prasugrel maintenance dose for all patients ≥75 years of age and those <75 years of age and <60 kg in weight were based on ancillary pharmacokinetic/pharmacodynamic data that suggested overexposure to the active metabolite with prasugrel 10 mg/d in both populations. 19, 20 The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (NCT00699998) was undertaken in 9326 patients with unstable angina/non-ST-segment-elevation myocardial infarction (UA/NSTEMI) managed medically without revascularization. 21, 22 TRILOGY ACS was designed to investigate the effects of prasugrel versus clopidogrel during a longer exposure period compared with previous trials of dual antiplatelet therapy in an understudied population, with a concomitant exploration of the safety of a 5-mg prasugrel maintenance dose in elderly patients (≥75 years of age). 22 Because superiority of prasugrel was not established in the primary cohort of 7243 participants <75 years of age (treated with prasugrel 10 mg/d, with 5 mg/d for these younger patients <60 kg in weight), the results of the exploratory analysis in 2083 participants ≥75 years of age have not yet been published. The present report provides the first long-term data on outcomes specifically from elderly participants in TRILOGY ACS, assesses the incidence and distribution of ischemic and bleeding end points by age, evaluates the safety of reduceddose prasugrel compared with clopidogrel in this elderly population, and assesses the association among body weight, bleeding risk, and pharmacodynamic response and reduceddose prasugrel compared with clopidogrel in elderly patients.
Methods
The design and primary results of TRILOGY ACS have previously been published. 21, 22 The study was performed in accordance with the Declaration of Helsinki, and national and local regulatory authorities approved the trial protocol in all participating countries and at all sites. All participants provided written informed consent.
Patients with UA/NSTEMI were eligible for enrollment if their treating physician decided on a final treatment strategy of medical management without revascularization within 10 days of presentation with their index event, if they had at least 1 of 4 risk criteria (age ≥60 years, diabetes mellitus, previous myocardial infarction [MI] , or previous revascularization with percutaneous coronary intervention or coronary artery bypass grafting [CABG]), and if they did not have an increased risk of major bleeding.
Randomization was stratified by treatment status with clopidogrel for the index event before randomization (no prerandomization clopidogrel treatment; clopidogrel treatment started in hospital for the index UA/NSTEMI event and continued until the day of randomization; and home clopidogrel treatment continued until the day of randomization). From June 2008 to September 2011, 9326 participants (<75 years of age, n=7243; ≥75 years of age, n=2083) were enrolled within 8 geographic regions comprising 52 countries. 22 All participants randomized to prasugrel who were ≥75 or <75 years of age and <60 kg in weight received a 5-mg/d maintenance dose; all participants randomized to clopidogrel received a 75-mg/d maintenance dose. Concomitant aspirin treatment was required, with ≤100 mg/d recommended. Study treatments were administered for a minimum of 6 months, and the maximum duration of treatment was 30 months for all patients regardless of age.
Statistical Analysis
The primary efficacy end point for the event-driven TRILOGY ACS trial was time to first occurrence of cardiovascular death, MI, or stroke. The trial was powered to show superiority of prasugrel over clopidogrel in the primary analysis cohort <75 years of age. 21, 22 The exploration of the 5-mg prasugrel maintenance dose in participants ≥75 years of age was not powered for efficacy. Formal sample-size analyses were not possible because long-term event rates in elderly UA/NSTEMI patients managed medically without revascularization were unknown. Therefore, the protocol specified an enrollment of a minimum of 2000 participants ≥75 years of age to provide a reasonable sample of patients to assess the safety of reduced-dose prasugrel compared with clopidogrel in this population. All efficacy analyses were performed on the intention-to-treat population that included all randomized patients (n=7243 for patients <75 years of age; n=2083 for patients ≥75 years of age). As previously detailed, bleeding end points (bleeding unrelated to CABG by Thrombolysis in Myocardial Infarction [TIMI] and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries [GUSTO] criteria) were evaluated by treatment assignment among participants who received at least 1 dose of study drug during the at-risk period of study drug treatment through 7 days after study drug discontinuation (n=7180 for patients <75 years of age; n=2060 for patients ≥75 years of age). 22 The effect of age on the primary efficacy composite end point, component end points, all-cause mortality, and bleeding end points was tested with Cox proportional hazards regression models, including an indicator for participants ≥75 years of age and clopidogrel stratum at randomization. P values were determined from log-rank tests stratified by clopidogrel treatment status as described above. Event rates within each age group are presented as the total number of events, the Kaplan-Meier event rate estimate at 30 months, and the 95% confidence intervals (CIs) for the Kaplan-Meier estimate. Among participants ≥75 years of age, data are presented similarly for the treatment comparison (prasugrel versus clopidogrel). We also by guest on April 12, 2017 http://circ.ahajournals.org/ Downloaded from tested the interactions between age <75 years versus age ≥75 years and randomized treatment assignment.
For the primary efficacy composite and non-CABG-related TIMI major bleeding end points, the relationship between age as a continuous variable and the end point was plotted with a linear spline. Predicted event rates at 2 years (y axis) were plotted by age (x axis); event rates came from proportional hazards regression modeling. Kaplan-Meier event curves were plotted for the primary efficacy composite and non-CABG-related TIMI major bleeding end-point rates during the 30 months of follow-up using 4 age strata (<75, 75-79, 80-84, and ≥85 years). Within the cohort ≥75 years of age, Kaplan-Meier event curves during the 30 months of follow-up were also compared between the prasugrel and clopidogrel groups. Histograms were used to show the proportion of time-to-first-event primary efficacy end points attributed to cardiovascular death, MI, or stroke in each age stratum. When patients had >1 primary endpoint component event, the event was categorized according to the first event (eg, MI followed by death was categorized as MI).
Given the observations that both age and lower body weight contributed to higher bleeding risk with standard-dose prasugrel (10 mg/d) in previous studies, we leveraged the data from the concomitant TRILOGY ACS platelet-function substudy for this analysis by exploring the impact of body weight on antiplatelet response and the safety of reduced-dose prasugrel versus clopidogrel in participants ≥75 years of age with 2 approaches. 16, 23 First, among the 515 participants ≥75 years of age (25% of the total elderly population) who were included in the TRILOGY ACS platelet-function substudy, the continuous relationship between body weight and on-treatment platelet reactivity unit (PRU) values measured at 30 days was evaluated within each randomized treatment group by assessing the correlation between weight and PRU. 23 We then tested the hypothesis that weight modifies the treatment effect on 30-day PRU values using an ANCOVA model. Second, the relationship between weight and the occurrence of non-CABG-related TIMI major or minor bleeding events was assessed in the entire sample of participants ≥75 years of age (n=2038) by comparing the weight of participants with and those Table 1 . Baseline Characteristics of Study Participants
All Participants
Participants ≥75 y of Age
Median age (25th, 75th percentiles), y without a bleeding event separately by treatment, as well as with the treatment-by-weight interaction.
All P values are 2 sided with a value of α<0.05 denoting statistical significance. Analyses were performed with SAS software, version 9.2 (SAS Institute).
Results
The largest proportion of participants ≥75 years of age were <80 years of age (1052 of 2083, 50.5%) at randomization, followed by those 80 to 84 years of age (n=656 of 2083, 31.5%) and those ≥85 years of age (n=375 of 2083, 18%). Compared with participants <75 years of age, elderly participants were more likely to be female and weigh <60 kg, to have NSTEMI rather than UA, to present with Killip class 2 or greater, and to have higher Global Registry of Acute Coronary Events (GRACE) risk scores and lower creatinine clearance values at baseline, and they were less likely to undergo angiography before randomization ( Table 1) .
The median duration of follow-up was 532 days (25th and 75th percentiles, 335 and 737 days) for participants <75 years of age versus 450 days (25th and 75th percentiles, 243 and 720 days) for those ≥75 years of age. The median duration of study drug treatment was 453 days (25th and 75th percentiles, 267 and 716 days) for younger participants compared with 364 days (25th and 75th percentiles, 179 and 642 days) for elderly participants.
Age-Related Outcomes
When evaluated continuously with a linear spline function, the predicted risk of the primary efficacy end point of cardiovascular death, MI, or stroke at 2 years increased in linear fashion until 70 years of age; thereafter, a sharp increase in risk of this end point was observed with increasing age ( Figure 1A ). In contrast, although the predicted risk of non-CABG-related TIMI major bleeding at 2 years increased in a linear fashion until ≈80 years of age; thereafter, the risk of this end point rose sharply with increasing age but with wide confidence bounds ( Figure 1B) .
The cumulative risks of both the primary efficacy end point and non-CABG-related TIMI major bleeding through 30 months rose progressively from the lowest to the highest prespecified age categories (Figure 2A and 2B) . The KaplanMeier estimate of the primary efficacy end point through 30 months was >2.5-fold higher in participants ≥75 years of age compared with those <75 years of age (35.7% versus 14.9%; hazard ratio [HR], 2.65; 95% CI, 2.37-2.97; Table 2 ). Similar differences were noted in the risk of MI and stroke between older and younger patients, but there was a proportionally higher age-related risk of both cardiovascular death (HR, 3.25) and all-cause death (HR, 3.27) compared with MI and stroke.
When the distribution of each of the component end points within the time-to-first-event analyses of the primary efficacy end point was evaluated across the prespecified age categories, the proportion of first events accounted for in the primary end-point ascertainment that were attributed to cardiovascular death appeared to rise only modestly (31% to 41%) from the lowest to the highest age categories (Figure 3) . In turn, the proportion of first events that were attributed to nonfatal MI declined modestly (60% to 51%) from the lowest to the highest age categories, with a relatively constant 9% to 10% of the first events attributed to nonfatal stroke across all age categories.
The risk of non-CABG-related bleeding assessed with both GUSTO and TIMI bleeding scales was 2-to 3-fold higher with older age ( 
Treatment Comparisons in Elderly Participants
The cumulative risk of the primary efficacy end point and non-CABG-related TIMI major bleeding through 30 months among participants ≥75 years of age was not significantly different with reduced-dose prasugrel compared with clopidogrel treatment, with overlapping event curves for both end points ( Figure 4A and 4B) . Similar results by treatment were demonstrated for all efficacy and bleeding end points (Tables 2 and 3 by guest on April 12, 2017 http://circ.ahajournals.org/ Downloaded from P value for stroke was 0.052 and for TIMI major/minor bleeding was 0.098. All other interaction P values for the outcomes listed in Tables 2 and 3 
Impact of Weight on Antiplatelet Response and Bleeding Events in Elderly Participants
Among 515 participants ≥75 years of age included in the platelet-function substudy, there was a significant positive correlation between lower 30-day on-treatment PRU values and lower body weight in the prasugrel treatment group (r=0.16, P=0.04), but no such correlation was observed in the clopidogrel treatment group (r=−0.04, P=0.58; Figure I in Figure II in the online-only Data Supplement).
Discussion
Our contemporary evaluation of ACS patients managed medically without planned revascularization provides several novel findings on the long-term relationships among age and efficacy and safety outcomes with extended dual antiplatelet therapy consisting of reduced-dose prasugrel for elderly participants. First, we observed only a modest increase in the proportion of participants with the first event of the primary efficacy composite end point attributed to cardiovascular death during prolonged follow-up with increasing age, with the majority of participants experiencing a nonfatal MI as the first event across all age categories. Second, there was a proportionally similar increased risk of both cardiovascular and major bleeding complications with increasing age. Third, we did not observe any differences in ischemic and bleeding outcomes between reduced-dose prasugrel (5 mg/d) and clopidogrel 75 mg/d in the elderly cohort. Finally, we did not observe a significant treatment-by-weight interaction when assessing 30-day on-treatment PRU values despite observing a positive correlation between lower PRU values with lower body weight only in the prasugrel group. Nonetheless, there was no difference in weight by occurrence of major bleeding events with either reduced-dose prasugrel or clopidogrel among participants ≥75 years of age.
Previous data from observational studies compared with pooled historical clinical trial populations of ACS patients demonstrate both a stepwise increase in the burden of comorbidities at presentation and increases in the risk of short-term ischemic events and bleeding complications with increasing age. 5, 6 Our data complement and extend these observations by demonstrating a substantially increased risk of both ischemic and bleeding events in elderly versus younger patients over a longer follow-up period compared with other recent ACS trials in the understudied, high-risk population of ACS patients managed without revascularization. Importantly, as noted above, we observed only a modest increase in likelihood of cardiovascular death as the first ischemic event with increasing age, and we observed that the increased risk of the component ischemic end points (cardiovascular death, MI, stroke) observed in older versus younger participants was proportionally highest for cardiovascular death. Additionally, we have shown a similar 2-to 4-fold increase in the risk of major bleeding complications in elderly participants, with a sharp upward trajectory in the rate of bleeding events with increasing age, findings that highlight the similar increased relative risk of both ischemic and bleeding events in elderly patients.
The adverse safety findings of the 10-mg prasugrel maintenance dose in elderly ACS patients treated with percutaneous coronary intervention, coupled with our exploratory findings from TRILOGY ACS, suggest that reducing the prasugrel maintenance dose to 5 mg/d appears to have mitigated the risk of serious bleeding in the elderly with no signal of efficacy in this exploratory analysis. 16 However, the absence of any increase in minor/moderate bleeding with this dose compared with clopidogrel 75 mg/d contrasts with results from the 10-mg prasugrel dose in the younger TRILOGY cohort, a finding that suggests a diminished degree of platelet inhibition with reduced-dose versus full-dose prasugrel. 22 A TRILOGY platelet-function substudy and a dedicated pharmacodynamics study in stable elderly participants with coronary disease confirmed an attenuated effect on platelet reactivity for 5-mg prasugrel in elderly participants relative to the 10-mg prasugrel dose tested in both younger and older cohorts, but in both studies, the antiplatelet effect of reduced-dose prasugrel was superior to that of clopidogrel. 23, 24 However, the 5-mg dose of prasugrel demonstrated similar suppression of platelet reactivity in elderly patients compared with younger patients (45-65 years of age). 24 Although a previous observational study showed a diminished pharmacodynamic response to both standarddose prasugrel (10 mg/d) and clopidogrel in elderly patients undergoing percutaneous coronary intervention, the impact of *Bleeding end points were evaluated by treatment assignment among participants who received at least 1 dose of study drug during the at-risk period of study drug treatment through 7 days after study drug discontinuation. Log-rank P values are shown for age and treatment comparisons. by guest on April 12, 2017 http://circ.ahajournals.org/ Downloaded from August 20, 2013 body weight on the findings was not reported. 25 In contrast, we observed only a weak correlation between lower PRU values at 30 days and lower weight among participants ≥75 years of age treated with reduced-dose prasugrel but not with clopidogrel, but there was no significant treatment-by-weight interaction. Additionally, we showed no differences in weight by the occurrence of infrequent major bleeding events in either treatment group. Collectively, the findings from our analysis add to previous studies by demonstrating that body weight does not appear to significantly affect the antiplatelet response and bleeding risk of reduced-dose prasugrel compared with standard-dose clopidogrel in elderly patients. However, the comparative safety of dosing regimens for both agents in elderly patients requires further assessment with a study that is adequately powered to evaluate differences in infrequent major bleeding events.
Although recent large-scale trials evaluating new antithrombotic therapies for the treatment of ACS did not restrict enrollment on the basis of age, we note that the proportion of patients ≥75 years of age enrolled in these trials was low (9%-17%), whereas in our study, patients ≥75 years of age made up 29% of the total population. [26] [27] [28] The proportion of elderly patients with UA/NSTEMI who underwent angiography and revascularization in these trials was substantially larger compared with studies from patients treated in routine practice. 1, 5 Indeed, the role of an invasive treatment strategy in elderly UA/NSTEMI patients remains uncertain and challenging to determine, as demonstrated in a trial dedicated to patients ≥80 years of age that was terminated prematurely as a result of slow enrollment. 29 Furthermore, a recent subgroup analysis of ACS patients ≥75 years of age in a large trial comparing P2Y 12 inhibitors demonstrated no difference in the safety profile of standard-dose ticagrelor over clopidogrel in elderly patients over 12 months, but ≈25% of these patients had STEMI and >60% underwent revascularization during the study. 30 In contrast, we evaluated the understudied medically managed population of UA/NSTEMI patients that was enriched with elderly patients over a prolonged (30-month) follow-up period, assessed the safety of a novel dosing regimen of prasugrel specifically designed to mitigate bleeding risks in the vulnerable elderly population, and ascertained the 
Study Limitations
Despite the relatively large sample of elderly participants studied in TRILOGY, some limitations should be noted. First, our study included only patients with ACS managed medically; thus, our results should not be extrapolated to patients who undergo revascularization. Second, our assessment of prasugrel versus clopidogrel in the elderly TRILOGY population was not powered for efficacy or safety, so results from this analysis should be considered exploratory and hypothesis generating. Third, study randomization typically occurred 4 to 5 days after hospital presentation, during which interval participants received open-label clopidogrel; thus, our study did not focus on the acute-care period for ACS patients. Fourth, we evaluated the relationship between body weight and antiplatelet response of reduced-dose prasugrel versus standard-dose clopidogrel, but the correlation between on-treatment PRU values and the risk of major bleeding with thienopyridine treatment has not been clearly delineated in previous studies. Finally, we assessed the impact of body weight on bleeding event occurrence by treatment group in participants ≥75 years of age, but the relatively small number of TIMI major/minor bleeding events limited the discrimination of this exploratory analysis.
Conclusions
Our findings demonstrate steeply increased trajectories in the risks of ischemic and bleeding events with increasing age among ACS patients managed without revascularization and no difference in the risks of both ischemic and bleeding outcomes with reduced-dose prasugrel versus clopidogrel in this exploratory analysis of elderly patients. Although it is encouraging that we did not observe a significant differential relationship among body weight, pharmacodynamic response, and bleeding risk with reduced-dose prasugrel versus clopidogrel in elderly patients, these exploratory findings highlight the challenges of investigating the dose selection for antiplatelet therapies in the high-risk elderly population. Therefore, large-scale clinical outcomes trials of antithrombotic therapies with adequate exposure of elderly ACS patients should be performed, potentially incorporating agespecific dosing regimens, to more clearly delineate optimal and safe treatment strategies for this vulnerable population.
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